We focus on the development of novel medicines using our proprietary Extreme Genetics® platform.

We are a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications that we intend to commercialize on our own, and for larger market indications that we intend to partner with global pharmaceutical industry leaders. We have built a core platform, which we call Extreme Genetics®, enabling the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. Our integrated platform has a full complement of in-house capabilities for human genetics and small molecule drug discovery, and for pre-clinical and clinical development.

Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short

News
July 1, 2015Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern to Discuss TV-45070 Phase 2b Study in Osteoarthritis Pain
July 1, 2015Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain
May 28, 2015Xenon to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference
May 22, 2015Xenon appoints Steven Gannon to its Board of Directors